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~ndotbe~ia~ injury represents a critical initiating event in the 
pathogenesis of various vascular disease entities ~ncinding 
spontaneous atherosclerosis. The prevalent view of sponta- 
neous atherosclerosis is the “response to injury” 
based on early proposals made by Virchow (1) 
quently modified by Ross (2) more than a century later. The 
thelial cell, leads to accumulation of lipid, which is the initial 
predominant feature in these vascular injury sites. Adhesion 
of monocytes and platelets, perhaps simultaneously at a later 
time, also occurs. These cells, together with the endothe~ 
hum, release various growth factors, ~e~di~~ to the later 
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proliferation of smoot ith 
chronic injury, the typical atherosclerotic plaque could form. 
A much accelerated version of this proliferative 
appears to be the cause of prem e coronary occlusion in 
patients undergoing heart tran ntatiou, coronary vein 
graft bypass and percutaneous transluminal coronary angio- 
plasty. This accelerated and premature atherosclerotic pro- 
cess accounts for significant morbidity and mortality in these 
patients (j-5). In COntraSt t0 SpOntaneOuS athtXOSC!e.~&i, a 
more significant denuding endothelial injury appears to be 
the critical initiating event, followed by intense platelet 
tion, leading to an initial 
muscle cell ~ro~~ferat~on 
(Table 1). 
This review will discuss :; 
vascular injury; 2) the resulta 
accnm~~ation and smooth muscle cell proliferation as 
ontaneous and accelerated atherogenesis; 3) 
syndromes of acceleratec’ atherosclerosis in transplanted 
heart atherosclerosis, caronary vein graft disease and reste- 
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Table 1. Comp&son Between the Processes of Spontaneous arid Accelerated Atherosclerosis 
Endothehaf injury 
Early platelet involvement 
Early monocyte jnvolvement 
Sources of growth factors 
Pathology 
Initial 
Late 
Complication 
Duration of process 
Spontaneous 
Atherosclerosis 
Type t 
t* 
EndotheliumlmonocyteI 
SMClplatelet 
Lipid deposition, 
monocyte and platelet 
adhesion 
Intima! SMC proliferation, 
fibrosis 
Plaque rupture, 
thrombosis 
Decades 
Accelerated 
Atherosclerosis 
Types 11 and III 
t 
EndotheliumlplateleUSMC 
Thrombosis, intimal SMC 
proliferation, fibrosis 
Lipid deposition 
Plaqiie rupture, 
thrombosis 
3 months to 2 years 
*If hypedpidemic. SMC = smooth muscle cells: + = present: - = absent. 
nosis after coronary angioplasty; and 4) emerging preventive 
strategies. 
V ar UrY 
Models of Vascular Injury 
Various experimental models of vascular injury have 
been developed to understand the importance of endothelial 
integrity and to study the cellular proliferative responses 
after endothelial injury and their roles in the pathogenesis of 
different vascular diseases. The categories of injury models 
currently available are the denuding and nondenuding forms 
of injury. Mechanical denudation of endothelium using dif- 
f;rost devices (such as balloon and nylon filament) are 
among the most widely used means of studying endothelial 
damage and are more applicable for the understanding of the 
syndromes of accelerated atherosclerosis (6-10). Diet- 
induced hypercholesterolemia is the most extensively stud- 
ied form of nondenuding injury; models closely resembling 
human spontaneous atherosclerosis include hypercholester- 
olemic swine and nonhuman primates (1 l-13). 
Denudiztion of EndMelhn: Mechanical and Immune Injury 
Balloon catheter lt@ry. Baumgartner and Spaet (6) were 
among the tlrst to introduce the balloon catheter to strip the 
endothelium from arteries. In subsequent studies (7-lo), the 
process of proliferative responses to balloon injury was well 
characterized. After complete endothelial denudation and 
various degrees of medial injury, immediate platelet aggre- 
gation and thrombus formation on subendothelium were 
observed. Several hours later, moderate numbers of leuko- 
cytes were also shown to adhere. The platelet aggregates 
persisted for up to 24 h after injury and subsequently 
flattened to form a multilayered carpet over the denuded 
area. At 48 h, some patchy regions of the injured area were 
reendothelialized by the migrating and dividing endothelial 
cells, particularly at the edge of the injury tract. At later 
stages, however, more severe areas of damage were covered 
by nonthrombog~~~c neointima composed of smooth muscle 
cells. Overall, there was a striking correlation between the 
degree of endothelial denudation and medial injury and the 
extent of myointimal thickening. 
Nylon catheter ‘my. Because balloon catheter injury 
can produce severe damage to the vascular subendothelium 
and media in addition to endothelial denudation, alternative 
techniques were devised to produce selective endothelial 
injury with minimal trauma to the intima. With the use of a 
small flexible nylon filament, endothelial injury of reproduc- 
ible depth and width could be produced without damage to 
the internal elastic lamina and the media (14-17). These 
confined endothelial denudations were accompanied by a 
moderate degree of platelet and leukocyte adhesion. In 
contrast to balloon injury, complete regeneration of the 
endothelium p>as evident by 48 h. No smooth muscle cell 
proliferation was observed. These data suggested that the 
degree or depth of trauma to the vessel wall was responsible 
for intimal thickening, particularly if endothelial regenera- 
tion took place early (16,17). Similar studies (16) also 
showed that the responses of the vascular cellular elements 
to a denuding injury were dependent on the way in which the 
endothelium was removed. In ad&ion, the rate of endothe- 
lial regeneration was much more rapid after superficial 
nylon-induced injury than after balloon injury and appeared 
to correlate with the lack of smooth muscle cell proliferation 
(17). Similarly, using an air-dry model for injury in rat 
carotid artccy, Fishman et al. (18) demonstrated maximal 
myointimal thickening in areas with minimal reendothelial- 
ization, indicating inhibition of smooth muscle growth by 
endothelial cells in regions of minimal injury. Indeed, Cast- 
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ne qmry. Alonso et a 
nectotis an 
s were more 
plaque rupture, could occur late in the 
of foreign protein and fed a 
rative fibrom~sc~lar intimal 
and evolved as atherosclerotic lesions closely resembling 
those seen in humans. Indeed, such immune mechanisms 
have been implicated in the pathogenesis of accelerated 
atherosclerosis in heart transplantation and probably play a 
role in the progression of spontaneous atherosclerosis. 
In the pathogenesis of spontaneous human atberosclero- 
sis, endothelial injury is unlikely to be mechanical. Further- 
more, failure to find significant morphologic changes and 
evidence of denudation has shifted emphasis to a search for 
more subtle forms of no~denudi~g injury at the molecular 
subcellular levels (2,26,27). etbods tbat might be 
applicable include endotoxin, anoxia, administration of car- 
bon monoxide, vasoactive amines, hypercholesterolemia 
and viral injury. Reidy and Schwartz (289 studied the mor- 
phology of aortic endothelium in rabbits after injury by a 
single dose of endotoxin and during subsequent repair. 
Within 1 h of the injection, some endothelia9 cells were 
rimarily mo~ocytes~ 
espite the vascular response, morphologic endothe~ial 
injury has not been described early in cholesterol die!- 
indmed atherosclerosis. Several studies (B 1,33-35) con- 
firmed the presence of intimal lesions 90 
recognizable 
olemia appea 
morphologic alteration &son and Gotto ( 
strated that hyp~rcholesterolemia can increase the ckoles- 
tero~phos~holipid ratio of endotbelial cell membrane and, 
subsequently, membrane viscosity. This change may be 
important in enhancing monocyte adhesion and the forma- 
tion of fatty streaks. Indeed, the adherence of monocytes to 
the arterial endotbelium has been shown (37,389 in vitro to 
increase in the presence of low density lipoproteins (LDL) or 
very low density lipoproteins (VLDL). In addition, the 
binding of monocytes to endothelium could be moduhted by 
the secretion of chemotactic factors by the arterial wall 
because such factors have been found in extracts of aorta 
from cholesterol-fed but not control swine (39,409. Werns et 
al. (41) recently demonstrated an abnormal response to 
vasoactive stimuli in segments of angiographica99y normal 
coronary arteries in patients with coronary artery disease. 
This vasomotor abnormality may in icate the presence of 
endothelial dysfunction early in atherogenesis. 
dn addition to endotheliai changes, hy,~ercholesterole~~a 
can cause functional aiterations in pIateIets and stnooth 
m&e cells and can accentuate the proliferative responses to 
endothelial injury. For example, lipoproteins can Caw a 
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change in platelet composition that can lead to activation (42). 
Indeed, enhanced platelet adhesion and aggregation have 
been observed in patients with hypercholesterolemia (42,43). 
Wus.induced endothelial iqjury. In 1973, Benditt and 
Benditt (44) provided evidence that cells composing some 
human atheromas are monoclonal in origin. These observa- 
tions have been conlirmed (45,46) and extended to include 
cells in organizing thrombi, and these studies prompted the 
search for viral or chemical mutants as the cause of myoint- 
imal proliferation. In 1979, Minick et al. (47) demonstrated 
that an atherosclerotic process resembling that in humans 
could be induced in normocholesterolemic chickens by 
infecting them with the Marek’s disease herpes virus. Mi- 
croscopically, arterial changes in infected animals were 
characterized by occlusive and fatty fibromuscular intimal 
thickening. Once again, endothelial denudation was not 
detectable during the early phase of the process. More 
recent experiments (48) have shed some light on the possible 
mechanisms of virus-induced endothelial damage; signifi- 
cantly greater cholesterol and triglyceride accumulation was 
observed in herpes simplex virus-infected human arterial 
cells than in uninfected cells. This accumulation apparently 
resulted from a decreased intracellular cholesterol hydroly- 
sis. Furthermore, infected cells have a reduced capacity to 
produce prostacyclin when stimulated. Prostacyclin has 
been shown to regulate platelet activity as well as cholesterol 
metabolism in smooth muscle cells in in vitro experiments 
(49). Thus, herpes virus can cause functional alternations of 
endothelial cells at the molecular level and appears to be an 
adequate stimulus for subsequent cellular proliferative re- 
sponses that closely resemble the human atherosclerotic 
process (48). 
Functional and Morphologic Classification of 
Vascular Injwy (Fig. 1) 
With this background, we propose the classification of 
vascular injury into three types. In type 1 there is functional 
alteration of endothelial cells without significant morpho- 
logic changes; in type II there are endothelial denudation and 
intimal damage, but internal elastic lamina and media are 
intact; and in type III there is endothelial denudation with 
damage of both intima and media. 
Thus, hypercholesterolemia appears to produce type I 
vascular injury, leading to monocyte and lipid accumulation 
and subsequent intimal hyperplasia; in addition, ruptured 
fatty plaque, which may occur later, may be considered as a 
type II/III injury that can lead to thrombus formation and 
organization. In the models of mechanical and immune 
injury, type II/III injury with intense platelet aggregation 
appears to be the prerequisite for the subsequent accelerated 
fibroproliferative responses and plaque formation. 
lar 
New information over the past few years concerning the 
role of lipoproteins and the various atheromatous cellular 
components (specifically, monocytes, lymphocytes, plate- 
lets and smooth muscle cells) in spontaneous atherogenesis 
has allowed us to speculate on the sequence of events after 
type I endothelial injury that result in formation of an 
atheromatous lesion. This sequence consists of 1) accumu- 
lation of monocytes, foam cell formation and interplay 
among lipoproteins, lymphocytes and other immune media- 
tors; 2) migration from the media and proliferation of smooth 
muscle cells in the intima to form a crescentic mass; 3) 
secretion and synthesis of extracellular matrix and collagen; 
and 4) at some point, the occurrence of plaque disruption 
(type II/III vascular injury) with resulting thrombosis, which 
may play an essential role in the progression of atheroscle- 
rosis and the manifestations of acute coronary syndromes. 
Monocyte Accumulation, Foam Cell 
Formation and Role of Lipoproteins and 
Immune Mechanisms 
onocyte accwnulatiou aud foam ce formation. More 
than 30 years ago, Poole and Florey (SO) presented evidence 
for the possible role of monocytes in the development of 
atherosclerotic lesions. Twenty years later, Gerrity et al. 
(13) reported that monocyte accumulation in subendothelial 
space was responsible for the formation of the fatty streak, 
an early lesion of atherosclerosis in cholesterol-fed swine. 
Subsequently, Ross (2) confirmed that monocyte invasion of 
the intima was the earliest cellular event in the evolution of 
an atherosclerotic lesion in monkeys and rabbits on an 
atherogenic diet. Recent studies (3 1,32,5 1,52) indicate that 
fatty streak foam cells in humans are also predominantly 
macrophages. The molecular mechanism underlying mono- 
cyte attachment to the vessel wall is unknown, but it appears 
to depend on the interaction between a series of glycopro- 
teins (GP) present on the monocyte surface (namely, GP-98, 
GP-168 and GP-155) and the monocyte binding sites on the 
endothelial surface (53,54). 
Possible mechanisms of increased monocyte adhesion to 
endothelium in hypercholesterolemia are just beginning to be 
examined and may involve the regulation of the expression 
of these receptor sites by various atherogenic stimuli (55). 
After accumulation in the subendothelial space, monocytes 
can secrete a large number of products that can participate in 
the initiation and evolution of the atherosclerotic lesion; 
thus, products such as interleukins, complement factor 
fragments and tumor necrosis factors can enhance monocyte 
adhesiveness and chemotaxis and form an amplification 
mechanism for recruiting more monocytes into the lesion 
(56). In addition, monocytes and macrophages can release 
re 1. Vascular injury an the syndromes ofacceler- 
atherosclerosis. Note hat early type IIS injary 
leadine: to acute thrombotic occlusion after vein araft 
implatktion and coronary angioplasty ( 
shown in the diagram; however, it 
accelerated atherosclerotic process. 
neous tramluminal coronary angi 
smooth muscle cells. 
3 months 
Endothelium 
lnlima 
Medlo 
Advenlitio 
I year 
Type I injury D 
TypelIiqury 
Type IIf qury 
Dysfunclionol 
endothelwm 
~Pldelet ond/ar mormcyte 
odhesion 
Thrombo$is /orgonieoticn 
Liptd deposition Ond 
SMC proli*eroPion 
SMC proliferation 
enzymes and oxygen-derived free radicals and may promote 
further endothehal injury and cytolysis. Released mitogens 
such as macrophage-derived growth factor may also play a 
key role on smooth muscle cell migration and subsequent 
proliferation (56). Finally, lipid uptake in the form of foam 
cells represents the major mechanism of lipid accumulation 
in the formation of fatty streak and early atheroma formation 
(51 X456). 
Be of lipoprotein m cations. Clinical studies (2,55) 
have shown that increased levels of LDL cholesterol con- 
tribute to the pathogenesis of atherosclerosis; howev-cA, the 
precise mechanisms remain unknown. Emerging evidence 
(57,58) suggests that various lipoprotein modifications (in 
particular, oxidative modification of LDL) may play a key 
role in the formation of fatty streaks and early atheromatous 
lesions. Recent investigations (59-61) have provided evi- 
dence that such oxidative modification of LDL may indeed 
occur in vivo. 
In vitro studies (57,58) suggest that oxidatively modified 
LDL may contribute to the atherogenic process by several 
mechanisms. First, and perhaps most important, oxidized 
rather than native LDL is recognized by the non-down- 
regulating scavenger receptors of macrophages and, thus, 
could promote foam cell formation. Second, modified LDL 
may be atherogenic by being chemotactic for monocytes, 
thereby potentially serving to recruit monocytes into the 
subendothelial space. Third, oxidized LDL is cytotoxic and 
may provide a potential mechanism for endothelial injury 
and cellular necrosis. 
~rnrnM~e ~~~an~~s in atherQge~~is~ Over the past few 
years, there has been a surge of new in 
cerning the potential relevance of 
atherogenesis. Studies (52X12,63) 
presence of substantial amounts of T lym 
early fatty lesions and in advanced fibrous lesions in hu- 
mans. In addition, the presence of T lymphocytes in the 
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intima is frequently associated with monocytes and macro- 
phages. Although the precise role of T lymphocytes in 
atherogenesis is still unknown and highly speculative. this 
close association with monocytes and macrophages is not 
surprising in view of the well known regulatory interactions 
between these two cell types (62). For example, the secre- 
tion of monocyte chemotactic factor can enhance the adhe- 
sion and migration of circulating monocytes; the release of 
lymphokines and interleukins from activated T lymphocytes 
can regulate lipoprotein uptake by the macrophage and thus 
may influence foam cell formation. In addition, the complex 
regulatory roles of these cytokines on the expression of 
growth factor receptors and smooth muscle cell growth raise 
the possibility that the T lymphocytes may play a pivotal role 
in atherogenesis (52,62). 
Other components of the immune system, such as immu- 
noglobulins and various activated complement factors, 
have also been identiffed in human atherosclerotic plaque 
(62,64,65). Although their mere presence does not necessar- 
ily imply a cause and effect relation, it may indicate an 
ongoing immune response in the atherosclerotic process. 
Seifert et al. (66) recently demonstrated the deposition of 
complements CSa-9 complex in the endothelial layer and 
intima in rabbits as early as 2 weeks after the start of a 
high fat diet, followed by monocyte accumulation and 
foam cell formation at the same sites of complement 
deposition at 6 weeks. Conversely, monocytes and macro- 
phages were not detected in locations devoid of comple- 
ment activation products. Certain complement peptides 
have been demonstrated to be chemotactic for monocytes 
(66). In addition, recent studies (67) of CS-binding proteins 
in human plaque demonstrated that the smooth muscle 
cells of the atherosclerotic lesion (but not of normal 
artery) express a decay-accelerating factor that protects 
the cells from complement-mediated lysis by inhibiting 
C3K5 convertase formation. This shows that the phenotypic 
changes in smooth muscle cells during atherogenesis 
may involve the induction of complement regulatory mole- 
cules. 
These provocative findings are just a few examples in a 
rapidly growing field regarding the role of immune mecha- 
nisms ir! atherogenesis. The interplay among these cellular 
components provides numerous potential mechanisms for 
mediating the inflammatory, repatitive and proliferative 
changes seen in atherosclerotic lesions. 
Smooth Muscle Cell Migration 
and froliferation 
Proliferation of smooth muscle ce!fs is a key prerequisite 
process leading to vascular occlusion in both sportraneous 
and accelerated atherosclerosis (Table I). Animal models of 
vascular injury designed for the study of the “response to 
injury” hypothesis have suggested that migration and sub- 
sequent proliferatioir of smooth muscle cells depend on the 
milieu created by ;he interactions between blood-borne cells 
and endothelium after the injury. Elimination of the growth 
inhibitory effect of intact endothelium and the release of 
growth factors from activated platelets, monocytes, injured 
endothelial cells and smooth muscle cells, coupled with 
thrombosis and thrombus organization, provide the mitoge- 
nit stimuli for smooth muscle cell growth. 
uscle cells: ~heno~pic 
Smooth Muscle CeUs From ‘~~ontracti~” to “Syn 
Behavior in cell culture. Vascular smooth muscle cells 
can express different phenotypes (68-70). In young devel- 
oping arteries, smooth muscle cells have the ability to 
proliferate and produce large amounts of collagen, elastin 
and proteoglycans. In the adult artery, their main firnction is 
to regulate wall tension, but they may modulate back into a 
synthetic phenotype and participate in tissue repair or 
atherogenesis. In forming atherosclerotic lesions, smooth 
muscle cells appear to regain the phenotypic characteristics 
of smooth muscle cells in young and developing arteries (69, 
70). Our knowledge of the signal or signals that initiate 
modulation into the synthetic phenotype is still very limited, 
but much has been learned of the behavior of smooth muscle 
cells in cell culture systems. Investigators (69,70) have 
studied the phenotypic changes in smooth muscle ceils in 
primary culture. Their studies demonstrated that when 
smooth muscle cells from the aortic media of young adult 
rabbits were dispersed into single cells such that a confluent 
monolayer was present, they attained the contractile state, 
characterized by a fusiform shape with abundant bundles of 
myofilaments in the cytoplasm, and could respond to me- 
chanical and electrical stimuli by slow contraction. If the 
isolated cells were sparsely seeded, they spontaneously 
underwent a change of phenotype to the synthetic state, with 
a loss of the thick myosin-containing filaments and an 
increase in synthetic matrix. These cells also became 
broader and flatter and lost their contractility. However, 
modulation into this synthetic state in vitro was inhibited if 
smooth muscle cells were grown on a confluent layer of 
endothelial cells. 
Phenotypic changes in vascular injury. Similar pheno- 
typic changes in medial smooth muscle cells from a contrac- 
tile to a synthetic mode have been demonstrated in various 
models of vascular injury (68.71-73). After massive endothe- 
lial loss from an artery, smooth muscle cells proliferate first 
in the media and later in the intima. In the balloon catheter- 
injured rat carotid artery, approximately 30% of the medial 
smooth muscle cells participated in the immediate prolifer- 
ative response, reaching a maximum at 48 h. These cells 
were ultrastructurally similar to the synthetic state cells in 
culture, with large amounts of rough endoplasmic reticulum, 
free ribosomes and mitochok&ia and fewer myofilaments. 
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ays, and was maxi 
into the ~~lima never divid 
play a role (7840). 
established as a key event ion ofat~erosc~erosis 
1 issues in atherogen- 
mica1 signai or signals 
that underlie smooth muscle celI proliferation. In the normal 
quiescent state, smooth muscle cells proliferate at a very low 
rate. Experimental evidence (18-20) suggests that intact 
endothelium plays the central role in maintaining the low 
proliferative state of smooth muscle cells under normal 
vascular conditions. In the case of type II and type III 
vascular injury, wbicb can be induced experimentally and 
which clearly occurs in humans at the perianastomotic area 
of vascular grafts and after coronary angioplasty, platelets, 
injured endothelial cells and smooth muscle cells can release 
platelet-derived growth factor and other mitogens necessary 
for smooth muscle cell growth. In type I injury, as in 
hypercholesterolemia, adherent monocytes and possibly 
dothelial and smooth muscle cells may secrete mitogens t 
can cause smooth muscle cell proliferation. 
of 
oe 
and smooth muscle cell proliferation suggest that intact 
endothelium is a potent inhibitor of the growth of smooth 
muscle cells; their proliferation ceases when a mechanically 
denuded area is reendothelialized. As previously discussed, 
ears to acc~rn~~ate 
ortion of chondrot 
synthetic state (8749). Sources 
macro~bages and smooth must cells. Their interactions 
play a significant role in promoting smooth muscle cell 
IateIe~. Platelets are excellent 
intimal plaque formation after 
type 1I and type III injury. In almost all in vivo experimental 
models studied (8-1~,16,26,72,7~), immediate platelet adhe- 
sion and degranulation were observed, followed by prolifer- 
of smooth muscle cells within 48 h of denudation. 
ic activity declines considerably thereafter as platelets 
appear. The fact that intimal thickening induced by mod- 
erate balloon catheter injury is significantly inhibited in 
rabbits with severe thrombocytopenia (90) lends additional 
support to the notion that platelet-derived growth factor may 
lay a role in the induction of the proliferative response after 
ascular injury. In a model of e~dothelial injury induced by 
~omocyst~~~emia, Harker et al. (91) demonstrated desqua- 
mation of endothelial cells, wed by platelet adbes~o~, 
thrombus formation, smooth cle cell migration from the 
media to the intima and subsequent proliferation leadia~ to 
intimal thickening; antiplatelet therapy with sultinpyiazone 
inhibited this process. In humans, it is highly likely that 
platelets are involved in earlv lesion formation in catheter- 
1674 IP ET AL. 
SYNDROMES OF ACCELERATED ATHEROSCLEROSIS 
JACC Vol. IS, No. 7 
June 1990:16fi7-87 
induced injury, in perianastomotic !eSiOnS Of VasCU!ar grafts 
and in other traumatic vascular injury. The role of platelets 
after type I injury is less certain, as indicated by severa! 
experimental models of atherosclerosis in which prolifera- 
tion of smooth muscle cells and intimal thickening can occur 
without obvious platelet participation (I 1,29-33). However, 
Fuster et al. (Z-94) demonstrated that normal pigs on a 
norma! or mildly hypercholestoleremic diet developed ex- 
tensive proliferative atheromatous lesions, whereas pigs 
homozygous for von Willebrand disease and thus lacking 
factor VIII and defective in platelet-vessel wa!! interaction 
developed less proliferative lesions. Similarly, thrombocyto- 
penia can reduce atherosclerotic lesions in rabbits (95). 
Indeed, although platelets may not be important in the 
initiation of atherosclerosis related to minima! injury (type 
I), they may play a role in subsequent progression of the 
disease (2). 
Platelet-derived growth factor is a major mitogen for 
smooth muscle cells. It is a 30 kd basic protein consisting of 
two disulfide-linked polypeptide chains (A and 5) and is one 
of the primary constituents of the platelet alpha-granule (96). 
One or both of its chains can also be synthesized by several 
other cells, including endothelia! cells, macrophages and 
smooth muscle cells. The early response to activation of the 
platelet-derived growth factor receptor on smooth muscle 
cells includes a tyrosine-specific autophosphorylation of the 
receptor in intracellular calcium and active exclusion of 
protons by means of the sodium-potassium exchanger. The 
end result is activation of several genes responsive to 
platelet-derived growth factor and production of their spe- 
cific proteins (W). These proteins probably play an essential 
role in such processes as smooth muscle cell proliferation 
and migration. 
St!mulat!ng effect by damaged endothelia! cells. Endothe- 
lia! ceP!s from every source tested, including bovine, monkey 
and pig aorta, rat heart and human umbilical vein, possess 
growth-promoting activity for cultured smooth muscle cells 
and fibroblasts (97). The mitogenic activity is due to the 
secretion of at least two major mitogens, which are separable 
by biochemical and immunologic methods (98-100). One of 
these mitogens is closely related if not identical to platelet- 
derived growth factor. The mechanism by which growth 
factor production is regulated in endothelia! cells is not 
known. The amount of growth factor production by cultured 
endothelial cells can be dramatically increased by increasing 
the PI-I or by lethally injuring the endothelia! cells with 
agents such as endotoxin and phobo! esters (99). A mathe- 
matic model (99) applied to these cell injury experiments 
suggests that a dying endothelia! cell produces as much 
growth factors in <3 days as does a healthy cell during a 19 
day period. These data support the modified version of the 
“response to injury” hypothesis, in which focal lethal dam- 
age to the endothelium can lead to increased loca! mitogenic 
activity that can attract and stimulate neighboring smooth 
muscle cells. In contrast, endothelia! cells wit 
tion may exert an inhibitory effect on neigh 
relevance of monocytes in atherogenesis, in addition to 
accumulation of lipid, appears to be related to their ability to 
stimulate smooth muscle cell growth (56,101). In studies 
(102) of wound repair in guinea pigs with monocytopenia and 
subsequently in tissue culture studies, fibroblast prolifera- 
tion was inhibited when the availability of monocytes was 
diminished. Conversely, fibroplasia was ulated by mac- 
rophage-conditioned media in vitro (!03,1 It was recently 
reported (105,106) that at least part of the macrophage- 
derived mitogenic activity is due to production of a growth 
factor similar if not identical to platelet-derived growth 
t of smooth m~sc!e eel 
ria! smooth muscle cells in primary culture can spontane- 
ously modulate from a contractile to a synthetic phenotype. 
This transition is followed by rapid growth, which is partly 
independent of exogenous mitogens and accompanied by 
endogenous production of a platelet-derived growth factor- 
like protein (68,73,107-109). The ability to grow in serum- 
free medium ceases as the cells reach confluence, but it 
reappears if a wound is produced in the culture. These cells 
have also been found to express genes for the A chain of the 
platelet-derived growth factor and to acquire the properties 
of young developing smooth muscle cells. In accordance 
with these findings, Walker et al. (108) reported that smooth 
muscle cells isolated from arterial intima 2 weeks after 
balloon catheter-induced injury produced 10 times as much 
platelet-derived growth factorlike substances as smooth 
muscle cells isolated from the media of uninjured arteries. 
Libby et a!. (110) recently demonstrated that smooth muscle 
cells isolated from atheroma could secrete mitogenic pro- 
teins, some of which resemble platelet-derived growth fac- 
tor. This capacity to produce endogenous, potentially self- 
stimulating rowth factors may help explain how replication 
of smooth muscle cells can begin early in atherogenesis, 
even when the endothelia! barrier remains morphologically 
intact. It can also explain why replication of smooth muscle 
cells can continue after aggregation of blood cells (platelets 
and monocytes) has ceased a few weeks after vascular 
injury. 
Many additional growth factors present in platelets and 
atheroma cells are mitogenic toward vascular myocytes and 
lead to other contractile and metabolic changes. These 
include interleukin-1, alpha- and beta-fibroblast growth fac- 
tors, serotonin and thrombospondin (79,80,11 l-l 13). Vari- 
ous neurotransmitters and hormones, such as catechol- 
amines and angiotensin 11, are likewise implicated in 
myocyte growth regulation (114,115). 
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th factors. These g~ycosaminoglycans appear to be of 
rtance in the binding of lipid into the arterial wall (84, 
arterial wall has abnormal elastin (85), and this fiber may 
play a role in enhancing lipid uptake; in 
utes significantly to calcification of 
more protein than the g~ycosaminog~ycans. There is gen- 
eral agreement that atherosclerotic plaque contains an 
increased concentration of glycoproteins (2) and that. as 
with other interstitial fibrils, arterial smooth muscle cells 
play a role in this synthesis when stimulated by growth 
factors. 
The concept offibrous tissue synthesis assumes that the 
endothelial injury with the resultant cellular interactions and 
the release of mitogens lead not only to the migration and 
proliferation of smooth muscle cells, but also to the synthe- 
sis by these cells of the fibrous tissue components. In 
addition, it appears that the chronic pulsatile distension of 
the arterial region also favors the synthesis of collagen by 
smooth muscle cells and, thus, the slow progression of 
atherosclerotic plaque. 
Z%qeae isru~t~o~ and Thrombosis 
Platelet aggregation, fissures and thro 
role of platelets in the initiation of spontaneous atheroscle- 
rosis is currently undefined. However, emerging evidence 
99’ ET AL. 1695 
ly reported that the 
ce overlying atberosclerot~c plaque in cor- 
stages of thrombosis and thrombus organization was almost 
is findi~~g suggests that 
with incorporation of thro 
of clinical symptoms. 
Further evidence supporting thrombosis and thrombus 
rt of plaque progression is provided by a 
i et al. (El), using monoclonal antibody 
fibrinogen and fibrin(ogen) degradation 
products. They demonstrated that in advanced and fi 
plaques, fibrin and fibrin-related products were detected in 
the intima, neointima and deeper medial layer, especially 
around areas with thrombus incorporation; these fibrin and 
related products were also found in small quantities in early 
lesions and in normal arteries. 
There are two potentially important metabolic sequelae 
of thrombus incorporation. First, incorporated thrombus has 
been demonstrated to enhance lipid uptake in the form of 
either beta-VLDL or modified LDL by means of their 
respective receptors on the macrophages (122). Second, 
thrombin generated during the process of thrombosis has 
recently been shown to promote smooth muscle cell prolif- 
eration, either by acting as a growth factor itself or by 
enhancing release of mitogens from platelets and endothelial 
cells (123.124). In contrast, platelet aggregation and throm- 
bosis after type I11 and type III injury appear to play the 
mqior role in the initiation of lesion formation in the SW 
dromes of accelerated atherosclerosis. 
Plaque disruption (type 11 and type 111 injury) with 
resultant intraluminal thrombosis also plays a fa~dame~ta~ 
role ipl the pathogenesis of the acute coronary vndromes of 
unstable angina, acute myocardial infarction and sudden 
cardiac death. It is beyond the scope of this review to 
discuss these pathogenic mechanisms. However, it is impor- 
tant to bear in mind that it is the degree of the vascular injurY 
1676 IP ET AL. 
SYNDROMES OF ACCELERATED ATHEROSCLEROSIS 
JACC Vol. 15, No. 7 
June 1990~1647-87 
Table 2. Possible Biologic Mechanisms of Risk Factors in 
Spontaneous Atherogenesis 
Biology Hyperlipidemia Hypertension Smoking Genetics 
Vascuk injury t t t 
- 
OYpe 1) 
Lipid depositiolti tt tt 
Monocytelplatelet + 
deposition 
Fibroinlimal t t tt 
proliferation 
Plaque disruption ttt tt 
(type IIIIII) 
Thrombosis t tt - 
t = mild; tt = moderate; ttt = severe: - = noeffect. 
and its corresponding pathophysiologic responses that rep 
resent the primary determinant of the severity of the acute 
coronary occlusion and the clinical outcomes. 
Role of risk factors (Table 2). Finally, detailed discussion 
of the roles of the epidemiologically significant atherogenic 
risk factors, such as hyperlipidemia, hypertension, smoking 
and genetic factors, is not possible in this review. However, 
their potential relation to the underlying pathophysiologic 
events in the process of spontaneous atherosclerosis de- 
serves special comment. As already discussed, hyperlipi- 
demia, at least in various animal models, induces type I 
endothelial injury, which enhances lipid deposition into the 
vessel wall and increases platelet and monocyte adhesion 
and thrombosis. More important, emerging evidence sug- 
gests that hyperlipidemia, by favoring lipid accumulation, 
may contribute to plaque fissure and rupture (type II/III 
iujury), leading to subsequent thrombus formation. Simi- 
larly, hypertension may initiate or perpetuate vascular in- 
jury, or both, and may enhance the resultant fibrocellular 
proliferative responses. In addition, hypertension may play a 
role in triggering acute plaque rupture caused by the effect of 
shear stress on the arterial wall. Smoking may also initiate 
vascular injury by its toxic effects on the endothelium and 
enhance platelet reactivity and thrombogenic tendency. Ge- 
netic factors other than hyperlipidemia may contribute to an 
exaggerated myointimal proliferative arterial response after 
endothelial injury. 
Pathophysiobgic Stages of Ather~c~erQtic 
stages and Initiating Factors (Tables 1 to 3; 
Fig. I) 
The Process of plaque formation in accelerated athero- 
sclerosis can be divided into four stages: 1) deep intimal 
injury; 2) interaction of blood-borne cells (platelets, mono- 
Wes and lymphocytes) and, most importantly, early throm- 
Table 3. Biologic Factors in the Pathogenesis of the Syndromes of 
Accelerated Atherosclerosis 
Transplant Vein Graft Coronary Angioplasty 
Atherosclerosis Atherosclerosis Restenosis 
Vascular injury II llRll 111 
Platelet/ t tt tt 
thrombosis 
Hyperlipidemia ttt tt ti- 
Immunologic t - 
Symbols as in Table 2. 
bosis; 3) smooth muscle cell migration and proliferation; and 
4) lipid accumulation leading to plaque rupture and late 
thrombosis. In contrast to spontaneous atherosclerosis, in 
accelerated atherosclerosis, type II and type III vascular 
injury appear to be the critical initiating events that lead to 
platelet aggregation, thrombosis and thrombus organization. 
Type II vascular injury occurs in patients after heart trans- 
plantation and coronary vein graft bypass, whereas type III 
vascular injury occurs in patients after coronary angioplasty . 
In contrast to spontaneous atherosclerosis, platelet aggrega- 
tion and thrombosis early in the formation of atherosclerotic 
lesions can be found in all three clinical situations (125428). 
Processes of lipoprotein modification and monocyte accu- 
mulation probably play an important role in the later stages 
of the atherosclerotic process in heart transplant and vein 
graft disease; however, their role in chronic restenosis after 
coronary angioplasty is unclear because the formation of the 
obWuctive lesion is secondary to excessive smooth muscle 
cell proliferation. 
The concept of immune-mediated atherogenesis in heart 
transplant-related atherosclerosis is controversial. Although 
immunoglobulin and complement deposition have been dem- 
onstrated in coronary arteries in heart transplant patients, 
most evidence for an immunologic basis for transplant 
atherosclerosis is circumstantial. However, it must be ac- 
knowledged that the establishment of a causal relation would 
be difficult, just as it has been for the relation between 
spontaneous atherosclerosis and hyperlipidemia and hyper- 
tension because of the many factors involved. The relative 
significance of the biologic factors in the pathogenesis of the 
syndromes of accelerated atherosclerosis is summarized in 
Table 3. 
Accelerated Atherosclerosis in Heart 
Transplantation (Fig. 1) 
Atherosclerosis in the transplanted heart is a serious and 
apparently irreversible complication of allogenic heart trans- 
plantation. Despite the improvement in supportive care, 
immunosuppressive methods and the use of antiplatelet 
drugs, the principal cause of death in those who survive the 
first postoperative year is premature coronary obstructive 
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* Incidence and Nature of Coronary Atherosclerosis in 
cart Fansplant ~eci~ie~ts* 
% Incidence 
Patients Lesions 
Time (yr) 
I 
3 
7 
Localization 
Diffuse alone (distal. ~2 yr) 
Discrete with or without diffuse 
(proximal, >2 yr) 
20 - 
45 - 
50 - 
- 24 (no collateral vessels) 
s_ 76 
*Data from references 134, 145 and 146. 
rosis defined angio- 
atherosclerosis are 
volvement. ~etranspla~tatio~ i 
Types of coronary lesions (Table 4). Gao et al. (134) 
recently studied the angiogra hit lesions in 81 transplant 
patients exhibiting coronary v scular disease and classified 
the lesions into two main types. The first, which tends to 
occur after the first postoperative year, is a Crete or 
tubular stenosis located mostly in primary epic ial coro- 
nary vessels and is similar in morphology to that of “ordi- 
nary atherosclerosis.” The second type, which tends to 
occur within the first postoperative year, is the most pre- 
dominant and the one discussed in this section; it is charac- 
terized by diffuse concentric narrowing located primarily 
in distal secondary and tertiary vessels. In the presence 
of total vessel obliteration, collateral vessels are poor 
or absent in >90% of cases. Pathoiogicahy, the vascular 
lesion is characterized by marked proliferation of intimal 
smooth muscle cells, with varying degrees of lipid accumu- 
lation and mononuclear cell infiltrates (24,126,135,136). Ad- 
ditionally, most large and severely involved segments have 
signs of old thrombus, with fibrous replacement and reca- 
nalization. 
Type II vascrrlar in&y. This appears to be the critical 
initiating event (Table 3) and leads to platelet deposition, 
mitogen release, subsequent smooth muscle cell prolifera- 
tion and collagen synthesis. At later stages, 
result of ruptured fatty plaque, thrombus formation and 
organization have been observed (126,135,136). The causes 
of type II vascular injury in transplanted hearts are likely to 
hoid cardiQ~~egia nd storage ( 137). 
at the time of excision can result in 
for atherogenesis is being 
t premature coronary artery 
ible rebtiQn between post- 
could cont~ib~tc to elevated ma iipidS, such as the use of 
corticosteroid and cyclosp therapy. Moreover, these 
factors may be superimposed on the primary background of 
hyperlipidemia, ~d~ic~iar~y in patients with un 
ischemic heart 
true-me ry. The concept of ongo- 
ing ~mrnu~e-mediated vascular injury as a cause of graft- 
related atherosclerosis is suggested by the demonstration of 
both bumoral and cellular components associated with vas- 
cular damage (52,143,144). The presence of cytotoxic cell 
antibody, which may be directed at an I-LA-BR antigen on 
the vascular endQthe~~um, was found to be a predictor Qf 
early myocardial infarction and sudden death in cardiac 
transplant recipients (145). The role of cellular immune 
mechanisms has been underscored by the findings that 
activated T lymphocytes and macrophages constitute a 
major proportion of cells in the atheromatous lesion (1441. 
Although the precise role of these immune mechanisms in 
the pathogenesis of accelerated atherosclerosis is still spec- 
ulative, these cells have a potentially significant ability. 
through their secretory products, to cause vascular injury 
and to stimulate monocyte and smooth muscle cell accumu- 
lation and lipid uptake. For example, the vascular effects of 
inter-let&ins released by activated T lymphocytes include 
induction of structural changes in endotheha! cells, mono- 
cyte and platelet accumulation and stimulation of smooth 
muscle cell proliferation and secretion of growth factors (52, 
79,80,144). Similarly, the effects of interferons, tUrnOr necrQ- 
sis factors and other cytokines on lipid metabolism 
and cell proliferation are well documented (52,144). of 
interest, however, immunosuppressive agents have not been 
shown to reduce the incidence or severity of disease in the 
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T&le 5. possible Biologic Mechanisms of Risk Factors in the Syndromes of Accelerated Atherosclerosis 
Transplant Atherosclerosis VeinGraB Disease Angioplasty Restenosis 
Etiology I'CEI Immune Hyperlipidemia ExVivolnjury Hyperlipidemia Balloon Shear Stress 
Vascular injury (II/III) tt tt t tt t t+ t 
Platelet deposition, t t tt t tt t 
thrombosis 
Fibrointimal proliferation t t tt t tt tt 
Lipid accumulation - +t tt 
Plaquedisruption tt tt 
FCEI = preimplantation coronary endothelial injury: symbols as in Table 2. 
transplanted heart, In fact, with the introduction of CYC~OS- 
porin and better control of the immune response and fewer 
acute rejection episodes, there has been no concomitant 
reduction in the development of accelerated atherosclerosis 
(146); this suggests a multifactorial nature of the pathogenic 
process. 
Role of antiplatelet agents. Because platelet deposition 
has been described as an initial event during endothelial 
necrosis, antiplatelet agents may have therapeutic value. 
Griepp et al. (147) demonstrated a reduction in the incidence 
of cardiac graft atherosclerosis and improvement of survival 
in patients treated with dipyridamole and warfarin. Although 
this study has several methodologic problems, recent uacon- 
trolled observations (148) on the use of antithrombotic 
agents suggest a beneficial effect, and therefore, controlled 
trials are worthwhile. 
Summary. Accelerated cardiac graft atherosclerosis ap- 
pears to share etiologic mechanisms with atherogenesis in 
the nontransplanted heart by means of the “response to 
injury” hypothesis. The potential risk factors and their 
possible roles in the pathogenesis of the atherosclerotic 
process are summarized in Table 5. Preimplantation coro- 
nary endothelial injury has been clearly demonstrated with 
current methods of cardiac preservation and storage. With 
the additive detrimental effects of denervation, immune 
injury and hyperlipidemia, the scene is set for initiation of 
the events that ultimately lead to the formation of occlusive 
fibrointimal disease. Our present knowledge of possible 
predisposing factors should lead us to focus more closely on 
potential therapeutic interventions including, among others, 
improving graft harvest and preservation technique and 
controlling serum lipids. 
Coronary Vein Graft Atherosclerosis (Fig. 1) 
Cmmry vein graB disease contributes to significant 
morbidity and mortality after coronary artery surgery and is 
responsible for the recurrence of angina pectoris, myocardial 
infarction and compromised ventricular function. Approxi- 
mately 10% of all grafts are occluded after the first or second 
week, and about 17% and 20% by 6 and 12 months, respec- 
tively, after operation. The occlusion rate is then 2% to 4% 
per year in those grafts still patent at 1 year. At the end of 5 
years, about 35% of vein grafts will be occluded (4,127,149- 
152). 
Vein graft disease can be divided into two main stages: 
an early postoperative stage of thrombotic occlusion related 
to a type III injury, and a late stage of accelerated athero- 
sclerosis secondary to a chronic type II injury, which begins 
within the first year and is due to fibrointimal proliferation. 
In the later years, lipid accumulation and thrombus form& 
tion and organization also occur (4,127,149-152). 
Type ocelusi~n (Table 
5). Vein grafts are subject to mechanical injury that may 
occur when the veins are harvested and handled during the 
operation, resulting in a transient predominantly type III 
injury, which may lead to acute thrombotic occlusion al- 
though in most cases the vessel wall heals quickly (151,153, 
154). With the exposure of the vein graft to a relatively high 
pressure flow and the presence of various biologic risk 
factors (such as hypercholesterolemia), a type II vascular 
injury may be induced and hinder the process of reendothe- 
lialization that might otherwise occur under normal condi- 
tions. This sets the stage for platelet deposition, lipid accu- 
mulation, growth factor release and subsequent fibrocellular 
proliferation. Indeed, vein grafts may show significant injury 
to the endothelial flow surface with marked platelet and 
leukocyte aggregation 24 h after implantation despite normal 
huninal morphology before the operation (154). Similarly, 
various animal graft models and human autopsy data (4, 
153-155) have demonstrated that early vein graft occlusion is 
thrombotic in origin. In addition to endothelial damage, 
arterialization of the vein graft results in a significant de- 
crease in vascular synthesis of the platelet antiaggregating 
prostacyclin; this may play a role in increasing the throm- 
bogenicity of vein grafts (154). 
Prevention of early graft occlusion. Clinical studies (149, 
156-161) have convincingly demonstrated a significant im- 
provement in graft patency rates at intervals ranging from 10 
to 360 days after operation when various antiplatelet regi- 
mens using aspirin, aspirin plus dipyridamole, sulfinpyra- 
zone and ticlopidine were instituted perioperatively as com- 
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the first year after operation, there is further connective 
tissue synthesis fro uscle ceils and fibrobiasts, 
foll by incorporation of lipid into the lesions. In the 
we of various biologic risk factors, such as byperiipi- 
demia and smoking, this process could be accelerated, 
leading to vascular occlusion. 
patients who had angiographic 
1 to 5 years after operation show typical histologic features 
of atherosclerosis: a mixture of fibrous plaque with intimal 
hyperplasia, ulceration, cholesterol clefts, foam ceils and, in 
some areas, calcification with disruption 0 medial layer 
(150,152,157). In addition, because of the isposition of 
fatty plaque to rupture (type III injury), occlusive or nonoc- 
elusive thrombus formation may aiso occur duritrg this late 
stage of graft disease, as documented in surgical s 
and autopsy studies (951,152,157,162); two thirds of vein 
grafts removed during a second coronary artery bypass 
operation may show evidence of mural or occlusive throm- 
bus (163). The beneficial effect of platelet inhibition in 
reducing late graft occlusion is less striking, but can be 
demonstrated (164). 
Preve&ion of late graft occluslor. No currently available 
agent prevents the accelerated atherosclerotic process in 
vein grafts resulting in late occlusion, although control of 
risk factors, such as cigarette smoking and hyperiipidemia, 
may be beneficial. The Cholesterol-Lowering Atberosciero- 
sis Study (165) reported that aggressive lowering of LDL 
cholesterol produced a significant reduction in new atheroma 
formation in bypass grafts in patients tested with choiestipoi 
and niacin. In a new trial on the prevention nf vein graft 
atherosclerosis, sponsored by the National Institutes of 
Health, the use of aspirin and lipid-lowering interventions 
alone or in combination will be tested. 
tients with coron 
5% of patients, whereas 
bus formation. Necrosis 0 
e~d~theli~m and pe 
progressive intimai proiiferati~~ of smooth muscle cells and 
reorganization of mural thrombus was evident at 90 to 14 
led to partial or complete occlusion 
mental studies (179,172) of aortoiliac 
d by mechanical injury in rabbits, 
nudation of endotheliai cells, piate- 
n and disruption artd splitting of 
e. Restenosis of the lumen occurred 
within 4 weeks. thologic analysis of the reste 
ments showed layers of proliferating smooth muscle ceils 
event in the pathogenesis of both acute occlusion and 
chronic restenosis. Immediate platelet aggregation and 
thrombus formation after vascular injury may account for 
the acute occlusion; mitogens released from platelets, endo- 
theiiai cells and smooth muscle ceils appear to be responsi- 
ble for the subsequent occlusive fibrointimal hyperpiasia. 
Indeed, autopsy data from 89 patients (reported at the time 
of this writing [928,173-1811) who died within days to 
months after successful angiopiasty suggest a similar se- 
quence of pathologic changes in the coronary arteries, 
leading to acute and late restenosis. Type III changes in the 
vessel wail seen in patients who died several days after 
angioplasty included focal denudation of the e~dotheiium, 
intimal necrosis, medial tear, adventitial bemorrbage a 
thrombosis. In some specimens, proliferating smooth muscle 
ceils were seen migrating from the media into the inrima, but 
with no remarkable hyperpiasia (175,179). 
Percutaneous coronary angioscopy provides direct visu- 
alization of the immediate morphologic changes in coronary 
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arteries induced by balloon angioplasty; thus, recent studies 
(182,183) describe mural thrombi, intimal flaps, dissection 
and ruptured atheroma as common findings. In contrast to 
the early morphologic features, specimens obtamed weeks 
to months after successful angitiplasty showed marked cir- 
cumferential fibrointimal thickening and organized thrombus 
at sites where chronic restenosis occurred (173-181). Simi- 
larly, tissues removed from restenotic vessels by atherec- 
tomy have been composed mainly of smooth muscle cells 
and collagen (184). 
Effects of shear stress (Table 5). The role of local shear 
stress in the pathogenesis of fibrointimal thickening after 
coronary angioplasty deserves special comment. Clinical 
observations (185) have demonstrated that a less than satis- 
factory residual stenosis >30% is associated with increased 
restenosis after angioplasty. The mechanisms by which a 
significant residual stenosis predisposes to restenosis is not 
entirely clear, but we postulate that two factors are involved. 
1) Using an extracorporeal perfusion chamber technique, we 
demonstrated (186) that platelet deposition was maximal in 
areas with high shear rate, such as at the site of a significant 
residual stenosis. Platelet deposition may then lead to 
growth factor release and subsequent smooth muscle cell 
proliferation causing restenosis. 2) Animal studies (187) of 
atherosclerosis and venous bypass grafts and human cadaver 
experiments (188) have demonstrated that intimal thickening 
tends to occur in areas of arteries with sudden changes in 
degree and direction of wall shear stress (oscillatory shear 
stress), and further evaluation has revealed that the degree 
of intimal thickness appears to correlate directly with the 
oscillatory shear stress. Oscillatory shear stress appears to 
enhance endothelial cell turnover (187,189), platelet deposi- 
tion (187) and smooth muscle cell proliferation (190: 191). If 
these concepts are applied to restenosis models after coro- 
nary angioplasty, any significant residual stenotic lesion will 
increase the distal flow separation and the oscillatory shear 
stress distal to the lesion. These changes will enhance 
intimal proliferation distal to the residual lesion and narrow 
the lumen. Thus, a residual stenotic lesion may enhance 
intimal proliferation and restenosis by the two rheologic 
mechanisms just described. In addition, severe damage or 
ulceration may further contribute to the restenosis process 
by enhancing platelet activation, thrombogenicity and 
smooth muscle cell proliferation. 
Prevention of R&en& 
Technical. Strategies to minimize vascular injury during 
balloon dilation, such as the use of nonthermal laser angio- 
PlastY (for example, the excimer laser) are currently under 
intense investigation. In addition, newer techniques to 
achieve optimal lumen size and blood flow could reduce the 
oscillatory shear stress and thus the intimal proliferation, 
For example, with the use of a perfusion catheter, inflation 
times can be prolonged and may optimize initial luminal 
results. Clinical trials with this technique are currently 
underway; however, it may increase vascular injury. Thus, 
an ideal technique would be one that could inflict the 
miGma1 degree of vascular injury and yet achieve an optimal 
rheology after dilation to minimize platelet deposition and 
smooth muscle cell proliferation. 
Pharmacologic. In experimental models of vascular in- 
jury (172,192), platelet inhibition appears to reduce the 
incidence of acute occlusion. In the clinical setting, three 
randomized controlled trials (193-195) demonstrated that 
pretreatment with antiplatelet agents (aspirin, aspirin plus 
dipyridamole or ticlopidine) significantly reduces the inci- 
dence of acute thrombotic occlusion and pe~procedural 
myocardial infarction. Heparin also has been suggested (196) 
to have a beneficial effect on acute occlusion in an experi- 
mental model of carotid angioplasty. The effects of an- 
tithrombotic therapy on late restenosis have been disap 
pointing. Clinical trials (195,197) using different platelet- 
inhibiting regimens have shown no impact on the restenosis 
rate. Similarly, anticoagulation with heparin or warfarin was 
of no benefit when compared with results achieved with 
aspirin (198,199). 
The ideal agent for preventing restenosis should itave 
antithrombotic or arstiproliferative efects, or both, witkoirt 
incurring the t-is& of bleeding complications. Recent re- 
search was centered on omega-3-fatty acids and low m&c- 
ular weight heparin, both of which appear to possess some af 
the characteristics of an ideal agent; Several clinica! studies 
(200-202) have provided evidence suggestive of a beneficial 
effect off&h oil in reducing the resrenosis rate after coronary 
angioplasty, but further trials are needed to confirm this 
effect. Results of research on nonanticoagulating, antiprolif- 
erative low molecular weight heparin appear to be promis- 
ing. Potential use of other agents, such as the more powerful 
antithrombotic drugs and growth factor antagonists, will be 
discussed next. 
Strategies to Prevent 
Accelerated Atherosclerosis 
Coronary artery disease remains the major cause of 
morbidity and mortality in the United States;, despite the 
decline during the past several years. In patients with left 
main coronary artery disease, triple vessel disease with 
compromised ventricular function and angtnal symptoms 
resistant to medical therapy, coronary artery bypass opera- 
tion is the standard therapy. In recent years, however, 
coronary angioplasty has been established as a safe and 
e@ective alternative to bypass surgery in up to 50% of 
patients requiring revascularization, and it can reduce the 
cost of medical care. For patients with end-stage heart 
disease, cardiac transplantation represents a viable thera- 
smooth muscle cell 
vascular occlusiou. 
ulating smooth muscle ccl 
various growth factors an 
~~o~iferat~~~ cellular responses. 
xtensive research is ~urreotly focu 
sponses in these clin 
as a nonthermal laser and other mechanical devices, may 
limit vessel wall injury in patients und 
angioplasty. The nature of type I injury in 
of spontaneous athe~os~lero5is remains 
until the precise in vivo echanism of injury can be identi- 
lied, intervention at thi 
modification of the potenti 
demia and smoking. 
Use of rnon~~~~~~ mtib iks. Platelet membrane recep- 
tors, such as glycoprotein IIWIIIa and won Willebrand 
factor, are esseatial for platelet aggregation and adhesion to 
the vessel wall. Specific antagonists of these receptor sites 
may have therapeutic potential. In a baboon vascular graft 
model, Hanson et al. (203) recently demoostrated that the 
use of monoclonal antibody against glycoprotein IIblIIIa 
complex resulted in a 72% reduction in acute graft closure 
secondary to thrombosis. Similarly, Bates et al. (204) 
showed a sign&ant reduction in acute coronary thrombosis 
after coronary angioplasty in dogs treated with the same 
monoclonal antibod Using the extraco perfusion 
chamber technique, a&won et al. C205) strated an 
81% reduction in platelet deposition on deendothelialized 
vessel wall and type I collagen in swine treated with mono- 
elonal amibody against von Willebrand factor compared 
dromes of accelerated atherosclerosis requires further ex- 
asic and experimental researc . The practical prob- 
hemostasis also need to be overcome. 
Excessive smooth m proliferation after vessel 
wall injury appears to ary to the effect of the 
growth factors released interacting cells and 
the loss of endothelial ~at~raIly occurring 
growth inhibitory substanc I pharmacologic ap- 
proaches to inhibit smooth muscle cell proliferation have 
In several experimental models (209,210), exog- 
ministered heparin has been shown to inhibit 
smooth muscle cell growth after vascular injury, but the 
doses required are prohibitively high. The use of short-term 
intravenous heparin after coronary angioplasty is common 
and may reduce the incidence of acute thrombotic occlusion, 
but it appears to have limited effect on chronic restenosis. 
Longer duration and higher doses of heparin have been 
proposed, but problems with difficulty of administration and 
hemostasis make it clinically impractical. The antiprolifera- 
tive effect of heparin is mediated by a functionally distinct 
moiety of the heparin molecule and appears to be due to 
inhibition of thymidine and uridine uptake by s 
cells. This blocks smootb muscle cell prolife 
GO/G1 growth state and prevents entry into the 
21%). Recently, Gordon et al. (213) demonstrated that arterial 
smooth muscle cell proliferation after balloon catheter injury 
was significantly reduced in rats receiving low molecular 
weight heparin, which has much less aoti~oagulating activ- 
ity. Thus, further development of nonanticoagulating an- 
1682 IP ET AL. 
SYNDROMES OF ACCELERATED ATHEROSCLEROSIS 
tiproliferative heparin analogs may have value in these 
clinical situations. 
~&reasedl platelet-derived growth factor production. in 
addition to having favorable effects on lipid concentration 
and platelet aggregability (214,215), fish oil has recently been 
shown in vitro to inhibit endothelial production of platelet- 
derived growth factorlike proteins (216). Several Clinical 
trials (200-202) have demonstrated lower rates of restenosis 
in patients receiving high dose omega-3-fatty acid after 
coronary angioplasty. Recently, using a cyclosporin-treated 
heart graft rat model, Saris et al. (217) demonstrated that fish 
oil supplementation significantly decreased the severity of 
coronary atherosclerosis in a transplanted allograft. The 
precise in vivo mechanism and the usefulness in the preven- 
tion of human transplanted heart atherosclerosis remain to 
be determined. 
Growth factor antagonist. A platelet-derived growth fac- 
tor antagonist, such as suramin, which inhibits platelet- 
derived growth factor binding at the receptor level, has not 
been extensively studied in experimental models of vascular 
injury, but it may have therapeutic potential (218). 
Other proliferative inhibitors. Recently, Powell et al. 
(219) demonstrated a significant reduction in intimal hyper- 
plasia in rat carotid artery after balloon catheter injury with 
the use of the angiotensin-converting enzyme inhibitor 
cilazapril. The precise antiproliferative mechanism of this 
agent is unknown, but its effect suggests a possible role of 
the angiotensin-converting enzyme in modulating the prolif- 
erative response after vascular injury. In this regard, angio- 
tensin II has been shown to induce a hypertrophic response 
in cultured rat smooth muscle cells and the expression of 
certain growth response genes (115,220,221). 
Lipoprotein modification. Finally, considerable progress 
in the understanding of the role of lipoprotein heterogeneity 
and its impact on atherogenesis has allowed development of 
new strategies in delaying and even reversing the process of 
both spontaneous and accelerated atherosclerosis. For ex- 
ample, the importance of lipoprotein modifications, specifi- 
cally oxidation, has renewed interest in antioxidants (57,58). 
In this context, probucol has been demonstrated to slow the 
progression of atherosclerosis in hyperlipidemic rabbits (59). 
In addition, realization of the role of reverse cholesterol 
transport in lipid metabolism has provided new avenues of 
future research. It has been demonstrated (222) for the first 
time that high density lipoprotein (HDL) plasma fractions 
inhibit fatty streak formation in cholesterol-fed rabbits. 
We have presented a pathologic classification of vascular 
injury and the resultant pathophysiologic responses leading 
to va~uhu occlusion. The potential roles of these responses 
in lipid deposition, intimal hyperplasia and thrombosis in the 
Pathologic process of spontaneous and accelerated athero- 
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sclerosis have been discussed. We believe that this classifi- 
cation and the resultant patbophysiologic cellular responses 
may increase our understanding of the pathogenesis of 
various vascular diseases and aid in formulating therapeutic 
and preventive strategies. 
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